How Should We Use Frailty Evaluation for Patients With Sepsis in the Clinical Practice?

The authors reply

“…Matsuda and Yamamoto (1) also raise an important point regarding our results of subgroup analysis. When evaluating subgroups, it is important to note that the question is not whether the subgroups have statistically significant results but whether the subgroup treatment effects are significantly different from each other, and a test of interaction is helpful to determine this (5).…”

“…We appreciate the thoughtful letter by Matsuda and Yamamoto (1) regarding our article (2). Matsuda and Yamamoto (1) raise an important consideration regarding how to use frailty for evaluation of patients with sepsis in the clinical practice and suggest that preexisting clinical frailty may be a new indicator for use of broad-spectrum antibiotics in patients with sepsis.…”

“…We appreciate the thoughtful letter by Matsuda and Yamamoto (1) regarding our article (2). Matsuda and Yamamoto (1) raise an important consideration regarding how to use frailty for evaluation of patients with sepsis in the clinical practice and suggest that preexisting clinical frailty may be a new indicator for use of broad-spectrum antibiotics in patients with sepsis. Herein, we investigated whether the preexisting clinical frailty is associated with an increased risk for multidrug-resistant (MDR) organisms in patients with sepsis by using a propensity score analysis.…”

“…Our analysis showed that the frail group was significantly associated with an increased risk for MDR organisms than the nonfrail group, even after adjustment for propensity score and potential confounders. As Matsuda and Yamamoto (1) suggested, the preexisting clinical frailty may be associated with an increased risk for multidrug-resistant organisms and used as a novel indicator for use of broad-spectrum antibiotics in patients with sepsis.…”